Search

Displaying results 391 - 400 of 536 in total
  1. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (

  2. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo.

  3. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

    Categories: Complex Mixtures
  4. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: SODIO FOSFATO MARCO VITI
  5. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]

  7. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.

  8. Drug

    Thiamine disulfide

    go.drugbank.com/drugs/DB15958
    Investigational

    Mixtures: Arca-Be Dragees
  9. Target

    Lys-63-specific deubiquitinase BRCC36

    go.drugbank.com/bio_entities/BE0009071
    TargetHumans

    Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). … Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites

    Synonyms: BRCA1-A complex subunit BRCC36, BRISC complex subunit BRCC36
  10. Target

    Cytochrome b

    go.drugbank.com/bio_entities/BE0004428
    TargetPlasmodium falciparum

    Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex) that is part of the mitochondrial respiratory chain. … The b-c1 complex mediates electron transfer from ubiquinol to cytochrome c. Contributes to the generation of a proton gradient across the mitochondrial membrane that is then used for ATP synthesis.

    Synonyms: Complex III subunit 3, Complex III subunit III